/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
Implications of ESC-high tthrombotic risk features and ARC-high bleeding risk criteria on clinical outcomes in all-comer patients undergoing PCI
Event: ESC Congress 2021 - The Digital Experience
Topic: Outcome
Session: Highlights from the Young in Intervention
New insights into optimal duration of DAPT for high-risk "TWILIGHT-like" patients with diabetes mellitus undergoing PCI: a focus on diabetes mellitus as a high-risk patient group
Event: ESC Congress 2021 - The Digital Experience
Topic: Adjunctive Pharmacotherapy
Session: Cardiovascular intervention: patient risk and technical features
Effect of risk enhancers versus technical aspects of high thrombotic risk criteria on adverse clinical events after PCI: insights from 2020 ESC NSTE-ACS Guidelines
Event: ESC Congress 2021 - The Digital Experience
Topic: Outcome
Session: Cardiovascular intervention: patient risk and technical features
Optimal strategy for antiplatelet therapy after coronary drug-eluting stent implantation in high-risk "TWILIGHT-like" patients with diabetes mellitus
Event: ESC Preventive Cardiology 2021
Topic: Pharmacotherapy
Session: Young Investigators Award Secondary Prevention and Rehabilitation
Usefulness of cardiometabolic index for the estimation of diabetes risk among general population in rural China: a community-based study
Event: ESC Preventive Cardiology 2021
Topic: Diabetes and the Heart
Session: Rapid fire abstracts - Primary Care and Risk Factor Management
Association of a favorable cardiovascular health profile (Life's Simple 7 and Fuster-BEWAT scores) with the presence of a newly proposed 4-tiered left ventricular hypertrophy
Event: ESC Preventive Cardiology 2021
Topic: Epidemiology
Session: Rapid fire abstracts - Primary Care and Risk Factor Management
The efficacy and safety of prolonged dual antiplatelet therapy beyond 12 months in patients with high risk of ischemic or bleeding events after PCI
Event: ACVC 2021
Topic: Antiplatelet Drugs
Session: Live Abstract session - Antithrombotics and bleeding
Benefit and Harm of Extended Dual Antiplatelet Therapy After PCI in high-risk TWILIGHT-like patients with acute coronary syndrome
Event: ACVC 2021
Topic: Treatment
Session: Live Abstract session - Antithrombotics and bleeding
Long-term ischemic and bleeding risk with extended dual antiplatelet therapy after PCI in patients with 2018 ESC/EACTS myocardial revascularization guideline-endorsed high thrombotic risk features.
Event: ACVC 2021
Topic: Cardiovascular Pharmacotherapy
Session: Live Abstract session - Antithrombotics and bleeding
Impact of ESC-endorsed high ischemic risk features and ARC-high bleeding risk criteria on clinical outcomes in all-comer patients undergoing PCI
Event: ACVC 2021
Topic: Percutaneous Coronary Intervention (PCI)
Session: ACVC Research Prize
ESC 365 is supported by
